nodes	percent_of_prediction	percent_of_DWPC	metapath
Irinotecan—Topoisomerase Inhibitors—Teniposide—lymphatic system cancer	0.424	0.569	CiPCiCtD
Irinotecan—Topoisomerase Inhibitors—Mitoxantrone—lymphatic system cancer	0.321	0.431	CiPCiCtD
Irinotecan—SLC22A3—Vincristine—lymphatic system cancer	0.0218	0.111	CbGbCtD
Irinotecan—ABCC1—Mitoxantrone—lymphatic system cancer	0.0207	0.105	CbGbCtD
Irinotecan—ABCG2—Teniposide—lymphatic system cancer	0.0198	0.101	CbGbCtD
Irinotecan—ABCC1—Vincristine—lymphatic system cancer	0.0143	0.0723	CbGbCtD
Irinotecan—ABCG2—Mitoxantrone—lymphatic system cancer	0.0139	0.0703	CbGbCtD
Irinotecan—CYP3A5—Teniposide—lymphatic system cancer	0.011	0.0557	CbGbCtD
Irinotecan—ABCC2—Vincristine—lymphatic system cancer	0.0106	0.0535	CbGbCtD
Irinotecan—ABCG2—Vincristine—lymphatic system cancer	0.00955	0.0484	CbGbCtD
Irinotecan—ABCC1—Methotrexate—lymphatic system cancer	0.00864	0.0438	CbGbCtD
Irinotecan—SLCO1B1—Methotrexate—lymphatic system cancer	0.00728	0.0369	CbGbCtD
Irinotecan—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.00705	0.0357	CbGbCtD
Irinotecan—CYP3A7—Vincristine—lymphatic system cancer	0.00705	0.0357	CbGbCtD
Irinotecan—ABCC2—Methotrexate—lymphatic system cancer	0.00639	0.0324	CbGbCtD
Irinotecan—ABCG2—Methotrexate—lymphatic system cancer	0.00578	0.0293	CbGbCtD
Irinotecan—CYP3A5—Vincristine—lymphatic system cancer	0.00529	0.0268	CbGbCtD
Irinotecan—ABCB1—Mitoxantrone—lymphatic system cancer	0.005	0.0254	CbGbCtD
Irinotecan—CYP3A4—Cytarabine—lymphatic system cancer	0.00435	0.0221	CbGbCtD
Irinotecan—CYP3A4—Teniposide—lymphatic system cancer	0.00429	0.0217	CbGbCtD
Irinotecan—ALB—Methotrexate—lymphatic system cancer	0.00398	0.0202	CbGbCtD
Irinotecan—ABCB1—Vincristine—lymphatic system cancer	0.00344	0.0175	CbGbCtD
Irinotecan—CYP3A4—Mitoxantrone—lymphatic system cancer	0.003	0.0152	CbGbCtD
Irinotecan—ABCB1—Methotrexate—lymphatic system cancer	0.00208	0.0106	CbGbCtD
Irinotecan—CYP3A4—Vincristine—lymphatic system cancer	0.00206	0.0105	CbGbCtD
Irinotecan—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000105	0.00182	CcSEcCtD
Irinotecan—Chills—Bleomycin—lymphatic system cancer	0.000105	0.00181	CcSEcCtD
Irinotecan—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000104	0.0018	CcSEcCtD
Irinotecan—Sweating—Vincristine—lymphatic system cancer	0.000104	0.0018	CcSEcCtD
Irinotecan—Renal failure—Mitoxantrone—lymphatic system cancer	0.000104	0.0018	CcSEcCtD
Irinotecan—Nausea—Mechlorethamine—lymphatic system cancer	0.000104	0.00179	CcSEcCtD
Irinotecan—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000104	0.00179	CcSEcCtD
Irinotecan—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.000103	0.00179	CcSEcCtD
Irinotecan—Alopecia—Bleomycin—lymphatic system cancer	0.000103	0.00179	CcSEcCtD
Irinotecan—Jaundice—Mitoxantrone—lymphatic system cancer	0.000103	0.00178	CcSEcCtD
Irinotecan—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000103	0.00178	CcSEcCtD
Irinotecan—Haemoglobin—Carmustine—lymphatic system cancer	0.000103	0.00177	CcSEcCtD
Irinotecan—Haemorrhage—Carmustine—lymphatic system cancer	0.000102	0.00176	CcSEcCtD
Irinotecan—Abdominal pain—Teniposide—lymphatic system cancer	0.000102	0.00176	CcSEcCtD
Irinotecan—Body temperature increased—Teniposide—lymphatic system cancer	0.000102	0.00176	CcSEcCtD
Irinotecan—Paraesthesia—Fludarabine—lymphatic system cancer	0.000102	0.00176	CcSEcCtD
Irinotecan—Sweating—Mitoxantrone—lymphatic system cancer	0.000101	0.00175	CcSEcCtD
Irinotecan—Dyspnoea—Fludarabine—lymphatic system cancer	0.000101	0.00175	CcSEcCtD
Irinotecan—Connective tissue disorder—Carmustine—lymphatic system cancer	0.0001	0.00173	CcSEcCtD
Irinotecan—Dyspepsia—Fludarabine—lymphatic system cancer	9.97e-05	0.00172	CcSEcCtD
Irinotecan—Dysarthria—Methotrexate—lymphatic system cancer	9.95e-05	0.00172	CcSEcCtD
Irinotecan—Ulcer—Methotrexate—lymphatic system cancer	9.95e-05	0.00172	CcSEcCtD
Irinotecan—Decreased appetite—Fludarabine—lymphatic system cancer	9.84e-05	0.0017	CcSEcCtD
Irinotecan—Visual impairment—Carmustine—lymphatic system cancer	9.83e-05	0.0017	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	9.77e-05	0.00169	CcSEcCtD
Irinotecan—Fatigue—Fludarabine—lymphatic system cancer	9.76e-05	0.00169	CcSEcCtD
Irinotecan—Pain—Fludarabine—lymphatic system cancer	9.68e-05	0.00167	CcSEcCtD
Irinotecan—Constipation—Fludarabine—lymphatic system cancer	9.68e-05	0.00167	CcSEcCtD
Irinotecan—Bradycardia—Mitoxantrone—lymphatic system cancer	9.65e-05	0.00167	CcSEcCtD
Irinotecan—Connective tissue disorder—Vincristine—lymphatic system cancer	9.57e-05	0.00165	CcSEcCtD
Irinotecan—Haemoglobin—Mitoxantrone—lymphatic system cancer	9.53e-05	0.00165	CcSEcCtD
Irinotecan—Rhinitis—Mitoxantrone—lymphatic system cancer	9.51e-05	0.00164	CcSEcCtD
Irinotecan—Hypersensitivity—Teniposide—lymphatic system cancer	9.49e-05	0.00164	CcSEcCtD
Irinotecan—Haemorrhage—Mitoxantrone—lymphatic system cancer	9.48e-05	0.00164	CcSEcCtD
Irinotecan—Flushing—Carmustine—lymphatic system cancer	9.47e-05	0.00164	CcSEcCtD
Irinotecan—Ill-defined disorder—Bleomycin—lymphatic system cancer	9.44e-05	0.00163	CcSEcCtD
Irinotecan—Pulmonary embolism—Methotrexate—lymphatic system cancer	9.41e-05	0.00163	CcSEcCtD
Irinotecan—Anaemia—Bleomycin—lymphatic system cancer	9.4e-05	0.00163	CcSEcCtD
Irinotecan—Feeling abnormal—Fludarabine—lymphatic system cancer	9.33e-05	0.00161	CcSEcCtD
Irinotecan—Asthenia—Teniposide—lymphatic system cancer	9.24e-05	0.0016	CcSEcCtD
Irinotecan—Malaise—Bleomycin—lymphatic system cancer	9.17e-05	0.00159	CcSEcCtD
Irinotecan—Arrhythmia—Carmustine—lymphatic system cancer	9.11e-05	0.00158	CcSEcCtD
Irinotecan—Leukopenia—Bleomycin—lymphatic system cancer	9.1e-05	0.00157	CcSEcCtD
Irinotecan—Cardiac disorder—Vincristine—lymphatic system cancer	9.04e-05	0.00156	CcSEcCtD
Irinotecan—Alopecia—Carmustine—lymphatic system cancer	9.01e-05	0.00156	CcSEcCtD
Irinotecan—Body temperature increased—Fludarabine—lymphatic system cancer	8.95e-05	0.00155	CcSEcCtD
Irinotecan—Cough—Bleomycin—lymphatic system cancer	8.88e-05	0.00153	CcSEcCtD
Irinotecan—Angiopathy—Vincristine—lymphatic system cancer	8.83e-05	0.00153	CcSEcCtD
Irinotecan—Diarrhoea—Teniposide—lymphatic system cancer	8.81e-05	0.00152	CcSEcCtD
Irinotecan—Mediastinal disorder—Vincristine—lymphatic system cancer	8.77e-05	0.00152	CcSEcCtD
Irinotecan—Alopecia—Vincristine—lymphatic system cancer	8.6e-05	0.00149	CcSEcCtD
Irinotecan—Back pain—Carmustine—lymphatic system cancer	8.59e-05	0.00148	CcSEcCtD
Irinotecan—Discomfort—Bleomycin—lymphatic system cancer	8.56e-05	0.00148	CcSEcCtD
Irinotecan—Chills—Mitoxantrone—lymphatic system cancer	8.51e-05	0.00147	CcSEcCtD
Irinotecan—Neoplasm—Methotrexate—lymphatic system cancer	8.5e-05	0.00147	CcSEcCtD
Irinotecan—Arrhythmia—Mitoxantrone—lymphatic system cancer	8.47e-05	0.00146	CcSEcCtD
Irinotecan—Alopecia—Mitoxantrone—lymphatic system cancer	8.38e-05	0.00145	CcSEcCtD
Irinotecan—Confusional state—Bleomycin—lymphatic system cancer	8.37e-05	0.00145	CcSEcCtD
Irinotecan—Hypersensitivity—Fludarabine—lymphatic system cancer	8.34e-05	0.00144	CcSEcCtD
Irinotecan—Oedema—Bleomycin—lymphatic system cancer	8.3e-05	0.00144	CcSEcCtD
Irinotecan—Anaphylactic shock—Bleomycin—lymphatic system cancer	8.3e-05	0.00144	CcSEcCtD
Irinotecan—Infection—Bleomycin—lymphatic system cancer	8.25e-05	0.00143	CcSEcCtD
Irinotecan—Anaemia—Carmustine—lymphatic system cancer	8.21e-05	0.00142	CcSEcCtD
Irinotecan—Back pain—Vincristine—lymphatic system cancer	8.2e-05	0.00142	CcSEcCtD
Irinotecan—Vomiting—Teniposide—lymphatic system cancer	8.19e-05	0.00142	CcSEcCtD
Irinotecan—Sepsis—Methotrexate—lymphatic system cancer	8.16e-05	0.00141	CcSEcCtD
Irinotecan—Thrombocytopenia—Bleomycin—lymphatic system cancer	8.13e-05	0.00141	CcSEcCtD
Irinotecan—Asthenia—Fludarabine—lymphatic system cancer	8.12e-05	0.0014	CcSEcCtD
Irinotecan—Rash—Teniposide—lymphatic system cancer	8.12e-05	0.0014	CcSEcCtD
Irinotecan—Dermatitis—Teniposide—lymphatic system cancer	8.11e-05	0.0014	CcSEcCtD
Irinotecan—Headache—Teniposide—lymphatic system cancer	8.07e-05	0.0014	CcSEcCtD
Irinotecan—Back pain—Mitoxantrone—lymphatic system cancer	7.98e-05	0.00138	CcSEcCtD
Irinotecan—Leukopenia—Carmustine—lymphatic system cancer	7.95e-05	0.00137	CcSEcCtD
Irinotecan—Anorexia—Bleomycin—lymphatic system cancer	7.91e-05	0.00137	CcSEcCtD
Irinotecan—Thrombophlebitis—Methotrexate—lymphatic system cancer	7.89e-05	0.00136	CcSEcCtD
Irinotecan—Anaemia—Vincristine—lymphatic system cancer	7.83e-05	0.00135	CcSEcCtD
Irinotecan—Hypotension—Bleomycin—lymphatic system cancer	7.76e-05	0.00134	CcSEcCtD
Irinotecan—Diarrhoea—Fludarabine—lymphatic system cancer	7.75e-05	0.00134	CcSEcCtD
Irinotecan—Hypertension—Carmustine—lymphatic system cancer	7.66e-05	0.00133	CcSEcCtD
Irinotecan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	7.66e-05	0.00132	CcSEcCtD
Irinotecan—Nausea—Teniposide—lymphatic system cancer	7.65e-05	0.00132	CcSEcCtD
Irinotecan—Anaemia—Mitoxantrone—lymphatic system cancer	7.63e-05	0.00132	CcSEcCtD
Irinotecan—Vertigo—Vincristine—lymphatic system cancer	7.61e-05	0.00132	CcSEcCtD
Irinotecan—Leukopenia—Vincristine—lymphatic system cancer	7.59e-05	0.00131	CcSEcCtD
Irinotecan—Paraesthesia—Bleomycin—lymphatic system cancer	7.45e-05	0.00129	CcSEcCtD
Irinotecan—Malaise—Mitoxantrone—lymphatic system cancer	7.44e-05	0.00129	CcSEcCtD
Irinotecan—Dyspnoea—Bleomycin—lymphatic system cancer	7.4e-05	0.00128	CcSEcCtD
Irinotecan—Renal failure acute—Methotrexate—lymphatic system cancer	7.4e-05	0.00128	CcSEcCtD
Irinotecan—Leukopenia—Mitoxantrone—lymphatic system cancer	7.39e-05	0.00128	CcSEcCtD
Irinotecan—Hypertension—Vincristine—lymphatic system cancer	7.32e-05	0.00127	CcSEcCtD
Irinotecan—Confusional state—Carmustine—lymphatic system cancer	7.31e-05	0.00126	CcSEcCtD
Irinotecan—Oedema—Carmustine—lymphatic system cancer	7.25e-05	0.00125	CcSEcCtD
Irinotecan—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	7.24e-05	0.00125	CcSEcCtD
Irinotecan—Decreased appetite—Bleomycin—lymphatic system cancer	7.22e-05	0.00125	CcSEcCtD
Irinotecan—Visual disturbance—Methotrexate—lymphatic system cancer	7.21e-05	0.00125	CcSEcCtD
Irinotecan—Cough—Mitoxantrone—lymphatic system cancer	7.2e-05	0.00125	CcSEcCtD
Irinotecan—Infection—Carmustine—lymphatic system cancer	7.2e-05	0.00124	CcSEcCtD
Irinotecan—Vomiting—Fludarabine—lymphatic system cancer	7.2e-05	0.00124	CcSEcCtD
Irinotecan—Rash—Fludarabine—lymphatic system cancer	7.14e-05	0.00123	CcSEcCtD
Irinotecan—Dermatitis—Fludarabine—lymphatic system cancer	7.13e-05	0.00123	CcSEcCtD
Irinotecan—Hypertension—Mitoxantrone—lymphatic system cancer	7.13e-05	0.00123	CcSEcCtD
Irinotecan—Pain—Bleomycin—lymphatic system cancer	7.1e-05	0.00123	CcSEcCtD
Irinotecan—Thrombocytopenia—Carmustine—lymphatic system cancer	7.09e-05	0.00123	CcSEcCtD
Irinotecan—Headache—Fludarabine—lymphatic system cancer	7.09e-05	0.00123	CcSEcCtD
Irinotecan—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	7.06e-05	0.00122	CcSEcCtD
Irinotecan—Cerebrovascular accident—Methotrexate—lymphatic system cancer	6.97e-05	0.0012	CcSEcCtD
Irinotecan—Discomfort—Mitoxantrone—lymphatic system cancer	6.94e-05	0.0012	CcSEcCtD
Irinotecan—Anaphylactic shock—Vincristine—lymphatic system cancer	6.92e-05	0.0012	CcSEcCtD
Irinotecan—Oedema—Vincristine—lymphatic system cancer	6.92e-05	0.0012	CcSEcCtD
Irinotecan—Anorexia—Carmustine—lymphatic system cancer	6.91e-05	0.00119	CcSEcCtD
Irinotecan—Infection—Vincristine—lymphatic system cancer	6.87e-05	0.00119	CcSEcCtD
Irinotecan—Feeling abnormal—Bleomycin—lymphatic system cancer	6.84e-05	0.00118	CcSEcCtD
Irinotecan—Osteoarthritis—Methotrexate—lymphatic system cancer	6.83e-05	0.00118	CcSEcCtD
Irinotecan—Confusional state—Mitoxantrone—lymphatic system cancer	6.79e-05	0.00117	CcSEcCtD
Irinotecan—Nervous system disorder—Vincristine—lymphatic system cancer	6.78e-05	0.00117	CcSEcCtD
Irinotecan—Thrombocytopenia—Vincristine—lymphatic system cancer	6.77e-05	0.00117	CcSEcCtD
Irinotecan—Hypotension—Carmustine—lymphatic system cancer	6.77e-05	0.00117	CcSEcCtD
Irinotecan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	6.74e-05	0.00116	CcSEcCtD
Irinotecan—Oedema—Mitoxantrone—lymphatic system cancer	6.74e-05	0.00116	CcSEcCtD
Irinotecan—Nausea—Fludarabine—lymphatic system cancer	6.72e-05	0.00116	CcSEcCtD
Irinotecan—Infection—Mitoxantrone—lymphatic system cancer	6.69e-05	0.00116	CcSEcCtD
Irinotecan—Hyperhidrosis—Vincristine—lymphatic system cancer	6.69e-05	0.00116	CcSEcCtD
Irinotecan—Shock—Mitoxantrone—lymphatic system cancer	6.63e-05	0.00115	CcSEcCtD
Irinotecan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	6.6e-05	0.00114	CcSEcCtD
Irinotecan—Anorexia—Vincristine—lymphatic system cancer	6.59e-05	0.00114	CcSEcCtD
Irinotecan—Body temperature increased—Bleomycin—lymphatic system cancer	6.56e-05	0.00113	CcSEcCtD
Irinotecan—Insomnia—Carmustine—lymphatic system cancer	6.55e-05	0.00113	CcSEcCtD
Irinotecan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	6.51e-05	0.00113	CcSEcCtD
Irinotecan—Paraesthesia—Carmustine—lymphatic system cancer	6.51e-05	0.00112	CcSEcCtD
Irinotecan—Hypotension—Vincristine—lymphatic system cancer	6.46e-05	0.00112	CcSEcCtD
Irinotecan—Dyspnoea—Carmustine—lymphatic system cancer	6.46e-05	0.00112	CcSEcCtD
Irinotecan—Somnolence—Carmustine—lymphatic system cancer	6.44e-05	0.00111	CcSEcCtD
Irinotecan—Anorexia—Mitoxantrone—lymphatic system cancer	6.42e-05	0.00111	CcSEcCtD
Irinotecan—Decreased appetite—Carmustine—lymphatic system cancer	6.3e-05	0.00109	CcSEcCtD
Irinotecan—Hypotension—Mitoxantrone—lymphatic system cancer	6.29e-05	0.00109	CcSEcCtD
Irinotecan—Insomnia—Vincristine—lymphatic system cancer	6.26e-05	0.00108	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	6.26e-05	0.00108	CcSEcCtD
Irinotecan—Paraesthesia—Vincristine—lymphatic system cancer	6.21e-05	0.00107	CcSEcCtD
Irinotecan—Pain—Carmustine—lymphatic system cancer	6.2e-05	0.00107	CcSEcCtD
Irinotecan—Constipation—Carmustine—lymphatic system cancer	6.2e-05	0.00107	CcSEcCtD
Irinotecan—Hypersensitivity—Bleomycin—lymphatic system cancer	6.12e-05	0.00106	CcSEcCtD
Irinotecan—Paraesthesia—Mitoxantrone—lymphatic system cancer	6.05e-05	0.00105	CcSEcCtD
Irinotecan—Decreased appetite—Vincristine—lymphatic system cancer	6.01e-05	0.00104	CcSEcCtD
Irinotecan—Dyspnoea—Mitoxantrone—lymphatic system cancer	6.01e-05	0.00104	CcSEcCtD
Irinotecan—Somnolence—Mitoxantrone—lymphatic system cancer	5.99e-05	0.00104	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	5.97e-05	0.00103	CcSEcCtD
Irinotecan—Feeling abnormal—Carmustine—lymphatic system cancer	5.97e-05	0.00103	CcSEcCtD
Irinotecan—Fatigue—Vincristine—lymphatic system cancer	5.96e-05	0.00103	CcSEcCtD
Irinotecan—Asthenia—Bleomycin—lymphatic system cancer	5.96e-05	0.00103	CcSEcCtD
Irinotecan—Dyspepsia—Mitoxantrone—lymphatic system cancer	5.93e-05	0.00103	CcSEcCtD
Irinotecan—Gastrointestinal pain—Carmustine—lymphatic system cancer	5.92e-05	0.00102	CcSEcCtD
Irinotecan—Pain—Vincristine—lymphatic system cancer	5.91e-05	0.00102	CcSEcCtD
Irinotecan—Constipation—Vincristine—lymphatic system cancer	5.91e-05	0.00102	CcSEcCtD
Irinotecan—Decreased appetite—Mitoxantrone—lymphatic system cancer	5.86e-05	0.00101	CcSEcCtD
Irinotecan—Fatigue—Mitoxantrone—lymphatic system cancer	5.81e-05	0.001	CcSEcCtD
Irinotecan—Pancreatitis—Methotrexate—lymphatic system cancer	5.79e-05	0.001	CcSEcCtD
Irinotecan—Pain—Mitoxantrone—lymphatic system cancer	5.76e-05	0.000996	CcSEcCtD
Irinotecan—Constipation—Mitoxantrone—lymphatic system cancer	5.76e-05	0.000996	CcSEcCtD
Irinotecan—Abdominal pain—Carmustine—lymphatic system cancer	5.73e-05	0.00099	CcSEcCtD
Irinotecan—Body temperature increased—Carmustine—lymphatic system cancer	5.73e-05	0.00099	CcSEcCtD
Irinotecan—Gastrointestinal pain—Vincristine—lymphatic system cancer	5.66e-05	0.000978	CcSEcCtD
Irinotecan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	5.55e-05	0.00096	CcSEcCtD
Irinotecan—Neutropenia—Methotrexate—lymphatic system cancer	5.52e-05	0.000954	CcSEcCtD
Irinotecan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	5.51e-05	0.000952	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	5.49e-05	0.000948	CcSEcCtD
Irinotecan—Abdominal pain—Vincristine—lymphatic system cancer	5.47e-05	0.000945	CcSEcCtD
Irinotecan—Body temperature increased—Vincristine—lymphatic system cancer	5.47e-05	0.000945	CcSEcCtD
Irinotecan—Hypersensitivity—Carmustine—lymphatic system cancer	5.34e-05	0.000923	CcSEcCtD
Irinotecan—Abdominal pain—Mitoxantrone—lymphatic system cancer	5.32e-05	0.000921	CcSEcCtD
Irinotecan—Body temperature increased—Mitoxantrone—lymphatic system cancer	5.32e-05	0.000921	CcSEcCtD
Irinotecan—Pneumonia—Methotrexate—lymphatic system cancer	5.29e-05	0.000915	CcSEcCtD
Irinotecan—Vomiting—Bleomycin—lymphatic system cancer	5.28e-05	0.000913	CcSEcCtD
Irinotecan—Rash—Bleomycin—lymphatic system cancer	5.23e-05	0.000905	CcSEcCtD
Irinotecan—Dermatitis—Bleomycin—lymphatic system cancer	5.23e-05	0.000904	CcSEcCtD
Irinotecan—Asthenia—Carmustine—lymphatic system cancer	5.2e-05	0.000899	CcSEcCtD
Irinotecan—Renal failure—Methotrexate—lymphatic system cancer	5.17e-05	0.000894	CcSEcCtD
Irinotecan—Stomatitis—Methotrexate—lymphatic system cancer	5.13e-05	0.000887	CcSEcCtD
Irinotecan—Hypersensitivity—Vincristine—lymphatic system cancer	5.1e-05	0.000881	CcSEcCtD
Irinotecan—Sweating—Methotrexate—lymphatic system cancer	5.04e-05	0.000872	CcSEcCtD
Irinotecan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	4.96e-05	0.000858	CcSEcCtD
Irinotecan—Asthenia—Vincristine—lymphatic system cancer	4.96e-05	0.000858	CcSEcCtD
Irinotecan—Diarrhoea—Carmustine—lymphatic system cancer	4.96e-05	0.000857	CcSEcCtD
Irinotecan—Nausea—Bleomycin—lymphatic system cancer	4.93e-05	0.000853	CcSEcCtD
Irinotecan—Asthenia—Mitoxantrone—lymphatic system cancer	4.83e-05	0.000836	CcSEcCtD
Irinotecan—Dizziness—Carmustine—lymphatic system cancer	4.79e-05	0.000828	CcSEcCtD
Irinotecan—Haemoglobin—Methotrexate—lymphatic system cancer	4.75e-05	0.000821	CcSEcCtD
Irinotecan—Diarrhoea—Vincristine—lymphatic system cancer	4.73e-05	0.000818	CcSEcCtD
Irinotecan—Haemorrhage—Methotrexate—lymphatic system cancer	4.72e-05	0.000817	CcSEcCtD
Irinotecan—Diarrhoea—Mitoxantrone—lymphatic system cancer	4.61e-05	0.000797	CcSEcCtD
Irinotecan—Vomiting—Carmustine—lymphatic system cancer	4.61e-05	0.000797	CcSEcCtD
Irinotecan—Dizziness—Vincristine—lymphatic system cancer	4.57e-05	0.000791	CcSEcCtD
Irinotecan—Rash—Carmustine—lymphatic system cancer	4.57e-05	0.00079	CcSEcCtD
Irinotecan—Dermatitis—Carmustine—lymphatic system cancer	4.56e-05	0.000789	CcSEcCtD
Irinotecan—Visual impairment—Methotrexate—lymphatic system cancer	4.55e-05	0.000787	CcSEcCtD
Irinotecan—Headache—Carmustine—lymphatic system cancer	4.54e-05	0.000785	CcSEcCtD
Irinotecan—Vomiting—Vincristine—lymphatic system cancer	4.4e-05	0.00076	CcSEcCtD
Irinotecan—Cardiac disorder—Methotrexate—lymphatic system cancer	4.38e-05	0.000758	CcSEcCtD
Irinotecan—Rash—Vincristine—lymphatic system cancer	4.36e-05	0.000754	CcSEcCtD
Irinotecan—Dermatitis—Vincristine—lymphatic system cancer	4.36e-05	0.000753	CcSEcCtD
Irinotecan—Headache—Vincristine—lymphatic system cancer	4.33e-05	0.000749	CcSEcCtD
Irinotecan—Nausea—Carmustine—lymphatic system cancer	4.3e-05	0.000744	CcSEcCtD
Irinotecan—Angiopathy—Methotrexate—lymphatic system cancer	4.29e-05	0.000741	CcSEcCtD
Irinotecan—Vomiting—Mitoxantrone—lymphatic system cancer	4.28e-05	0.000741	CcSEcCtD
Irinotecan—Immune system disorder—Methotrexate—lymphatic system cancer	4.27e-05	0.000738	CcSEcCtD
Irinotecan—Mediastinal disorder—Methotrexate—lymphatic system cancer	4.26e-05	0.000736	CcSEcCtD
Irinotecan—Rash—Mitoxantrone—lymphatic system cancer	4.25e-05	0.000734	CcSEcCtD
Irinotecan—Dermatitis—Mitoxantrone—lymphatic system cancer	4.24e-05	0.000734	CcSEcCtD
Irinotecan—Chills—Methotrexate—lymphatic system cancer	4.24e-05	0.000733	CcSEcCtD
Irinotecan—Headache—Mitoxantrone—lymphatic system cancer	4.22e-05	0.00073	CcSEcCtD
Irinotecan—Alopecia—Methotrexate—lymphatic system cancer	4.17e-05	0.000722	CcSEcCtD
Irinotecan—Nausea—Vincristine—lymphatic system cancer	4.11e-05	0.00071	CcSEcCtD
Irinotecan—Nausea—Mitoxantrone—lymphatic system cancer	4e-05	0.000692	CcSEcCtD
Irinotecan—Back pain—Methotrexate—lymphatic system cancer	3.98e-05	0.000688	CcSEcCtD
Irinotecan—Ill-defined disorder—Methotrexate—lymphatic system cancer	3.82e-05	0.00066	CcSEcCtD
Irinotecan—Anaemia—Methotrexate—lymphatic system cancer	3.8e-05	0.000657	CcSEcCtD
Irinotecan—Malaise—Methotrexate—lymphatic system cancer	3.71e-05	0.000641	CcSEcCtD
Irinotecan—Vertigo—Methotrexate—lymphatic system cancer	3.69e-05	0.000639	CcSEcCtD
Irinotecan—Leukopenia—Methotrexate—lymphatic system cancer	3.68e-05	0.000636	CcSEcCtD
Irinotecan—Cough—Methotrexate—lymphatic system cancer	3.59e-05	0.00062	CcSEcCtD
Irinotecan—Discomfort—Methotrexate—lymphatic system cancer	3.46e-05	0.000598	CcSEcCtD
Irinotecan—Confusional state—Methotrexate—lymphatic system cancer	3.38e-05	0.000585	CcSEcCtD
Irinotecan—Anaphylactic shock—Methotrexate—lymphatic system cancer	3.36e-05	0.00058	CcSEcCtD
Irinotecan—Infection—Methotrexate—lymphatic system cancer	3.33e-05	0.000576	CcSEcCtD
Irinotecan—Nervous system disorder—Methotrexate—lymphatic system cancer	3.29e-05	0.000569	CcSEcCtD
Irinotecan—Thrombocytopenia—Methotrexate—lymphatic system cancer	3.29e-05	0.000568	CcSEcCtD
Irinotecan—Hyperhidrosis—Methotrexate—lymphatic system cancer	3.24e-05	0.000561	CcSEcCtD
Irinotecan—Anorexia—Methotrexate—lymphatic system cancer	3.2e-05	0.000553	CcSEcCtD
Irinotecan—Hypotension—Methotrexate—lymphatic system cancer	3.14e-05	0.000542	CcSEcCtD
Irinotecan—Insomnia—Methotrexate—lymphatic system cancer	3.04e-05	0.000525	CcSEcCtD
Irinotecan—Paraesthesia—Methotrexate—lymphatic system cancer	3.01e-05	0.000521	CcSEcCtD
Irinotecan—Dyspnoea—Methotrexate—lymphatic system cancer	2.99e-05	0.000517	CcSEcCtD
Irinotecan—Somnolence—Methotrexate—lymphatic system cancer	2.98e-05	0.000516	CcSEcCtD
Irinotecan—Dyspepsia—Methotrexate—lymphatic system cancer	2.95e-05	0.000511	CcSEcCtD
Irinotecan—Decreased appetite—Methotrexate—lymphatic system cancer	2.92e-05	0.000504	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	2.9e-05	0.000501	CcSEcCtD
Irinotecan—Fatigue—Methotrexate—lymphatic system cancer	2.89e-05	0.0005	CcSEcCtD
Irinotecan—Pain—Methotrexate—lymphatic system cancer	2.87e-05	0.000496	CcSEcCtD
Irinotecan—Feeling abnormal—Methotrexate—lymphatic system cancer	2.77e-05	0.000478	CcSEcCtD
Irinotecan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	2.74e-05	0.000475	CcSEcCtD
Irinotecan—Abdominal pain—Methotrexate—lymphatic system cancer	2.65e-05	0.000459	CcSEcCtD
Irinotecan—Body temperature increased—Methotrexate—lymphatic system cancer	2.65e-05	0.000459	CcSEcCtD
Irinotecan—Hypersensitivity—Methotrexate—lymphatic system cancer	2.47e-05	0.000428	CcSEcCtD
Irinotecan—Asthenia—Methotrexate—lymphatic system cancer	2.41e-05	0.000416	CcSEcCtD
Irinotecan—Diarrhoea—Methotrexate—lymphatic system cancer	2.3e-05	0.000397	CcSEcCtD
Irinotecan—Dizziness—Methotrexate—lymphatic system cancer	2.22e-05	0.000384	CcSEcCtD
Irinotecan—Vomiting—Methotrexate—lymphatic system cancer	2.13e-05	0.000369	CcSEcCtD
Irinotecan—Rash—Methotrexate—lymphatic system cancer	2.12e-05	0.000366	CcSEcCtD
Irinotecan—Dermatitis—Methotrexate—lymphatic system cancer	2.11e-05	0.000366	CcSEcCtD
Irinotecan—Headache—Methotrexate—lymphatic system cancer	2.1e-05	0.000364	CcSEcCtD
Irinotecan—Nausea—Methotrexate—lymphatic system cancer	1.99e-05	0.000345	CcSEcCtD
